Evaluation of the Filler Performance on the Nasolabial Folds of Aliaxin® EV With and Without Lidocaine 0.3%

NACompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 28, 2017

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Nasolabial Folds Correction
Interventions
DEVICE

Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%

"The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."

DEVICE

Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)

"The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."

Trial Locations (1)

20900

DermIng S.r.l. Single Member Company, Monza

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Derming SRL

OTHER